In a study published in 2008, endosialin was found expressed in 8 out of 10 synovial sarcoma tumor specimens:
http://clincancerres.aacrjournals.org/content/14/22/7223.full
Morphotek Inc. is now leading a clinical trial for a monoclonal antibody(MORab-004) recognizing endosialin:
http://clinicaltrials.gov/ct2/show/study/NCT00847054
The first results of this phase I trial were presented at ASCO:
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84795
The company just received orphan drug designation from the FDA for this drug:
http://finance.yahoo.com/news/Morphotek-Inc-Announces-That-prnews-514907904.html?x=0&.v=1